Dercum Disease — Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033
Adiposis dolorosa, also known as Dercum Disease, is a rare disorder affecting subcutaneous tissue. It is characterized by the development of painful adipose tissue, often accompanied by multiple subcutaneous lipomas. This condition is frequently associated with being overweight or obese and typically emerges between the ages of 35 and 50. The primary symptoms include obesity and painful adipose tissue, with lipomas commonly appearing on the extremities, trunk, pelvic region, and buttocks. The pain is often described as burning or aching, though it can vary from person to person. The exact cause of adiposis dolorosa remains unknown. However, various hypotheses have been suggested, such as endocrine dysfunction, nervous system issues, mechanical pressure on nerves, adipose tissue dysfunction, inflammation, infection, and trauma or medication-induced factors. These hypotheses are based mainly on case reports and lack substantial evidence. Diagnosing adiposis dolorosa relies on two primary criteria: general overweight or obesity and chronic pain lasting more than three months in the adipose tissue. Diagnosis is established through a comprehensive physical examination and the exclusion of other possible causes, as there are no specific laboratory markers for this condition. Adiposis dolorosa is a chronic condition, and case reports indicate that pain tends to worsen over time. Although numerous therapeutic approaches have been attempted, no standardized treatment for this disease exists.
Thelansis’s “Dercum Disease Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report — 2023 To 2033” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Dercum Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Dercum Disease across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Dercum Disease Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Tags: Dercum Disease, Dercum Disease market outlook, Dercum Disease competitive landscape, Dercum Disease market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)
